Cover Image

Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey

Abstract Introduction While multiple treatments are available for moderate to severe psoriasis, patient preferences are rarely systematically studied. This study aims to identify factors associated with choice of a new once-daily oral psoriasis treatment, elicit patient views on treatment characteri...

Full description

Saved in:

Bibliographic Details
Main Authors:	April W. Armstrong (Author), Sayeli Jayade (Author), Sanika Rege (Author), Namita Joshi (Author), Vardhaman Patel (Author), Samaneh Kalirai (Author), Daniel Wolin (Author), Kimberly Boyle (Author), Dipen Patel (Author), Lauren Seigel (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2024-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluating prevalence and consequence of residual disease in individuals with psoriasis receiving apremilast treatment: results from a US patient survey
by: Tina Bhutani, et al.
Published: (2024)

Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors
by: Lana Schmidt, et al.
Published: (2023)

Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
by: Jashin J. Wu, et al.
Published: (2023)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023)

Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023)

Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis
by: April W. Armstrong, et al.
Published: (2024)

Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2024)

Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States
by: Sang Hee Park, et al.
Published: (2024)

Patient satisfaction with anaesthesia services in a tertiary care cancer centre. (SAY study)
by: Reshma Ambulkar, et al.
Published: (2022)

Pain management practices for outpatients with breast cancer
by: Ashna Talwar, et al.
Published: (2022)

Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States
by: April W. Armstrong, et al.
Published: (2023)

Antimicrobial Use Rates by Patient Care Units using NHSN Antimicrobial Use Option in TN Reporting Facilities, 2015-2023
by: Dipen M Patel, et al.
Published: (2024)

Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis
by: April W. Armstrong, et al.
Published: (2024)

Patient preferences for treatment attributes in moderate-to-severe atopic dermatitis: a discrete choice experiment
by: Steven R. Feldman, et al.
Published: (2024)

Real-world use of inhaled nitric oxide therapy in patients with COVID-19 and mild-to-moderate acute respiratory distress syndrome
by: Steven H Abman, et al.
Published: (2022)

Identifying Predictors of PASI100 Responses up to Month 12 in Patients with Moderate-to-severe Psoriasis Receiving Biologics in the Psoriasis Study of Health Outcomes (PSoHO)
by: April W. Armstrong, et al.
Published: (2024)

Patient preferences for atopic dermatitis treatments: a discrete choice experiment
by: Shawn G. Kwatra, et al.
Published: (2023)

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials
by: April W. Armstrong, et al.
Published: (2024)

Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe
by: Anthony Bewley, et al.
Published: (2024)

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey
by: Joe Gorelick, et al.
Published: (2019)

Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
by: Peter A. Lio, et al.
Published: (2024)

Correction to: Burden of Topical Treatments in Psoriasis and Preferred Criteria of Choice: A Survey-Based Evaluation of Patients in Europe
by: Anthony Bewley, et al.
Published: (2024)

Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies
by: Linda Stein Gold, et al.
Published: (2023)

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
by: April Armstrong, et al.
Published: (2019)

Respecting the Patient's Choice: A Case of Possible Drug-Induced Parkinsonism
by: Megan R. Undeberg, et al.
Published: (2022)

Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States
by: Teri Greiling, et al.
Published: (2024)

Improvement in general touch avoidance in patients with moderate‐to‐severe genital psoriasis treated with ixekizumab during a 52‐week, randomized, phase 3 clinical trial (IXORA‐Q)
by: Jennifer Soung, et al.
Published: (2023)

Treatment burden and the perspectives of patients with psoriasis using topical treatments: results from a national survey of adults with psoriasis in the United States
by: April Armstrong, et al.
Published: (2024)

Brodalumab to the Rescue: Efficacy and Safety of Brodalumab in Patients with Psoriasis and Prior Exposure or Inadequate Response to Biologics
by: Alan Menter, et al.
Published: (2020)

Assessment of nutritional status in chronic periodontitis patients: A cross-sectional study
by: Anuradha Bhatsange, et al.
Published: (2024)

Anticytokine therapy with interleukin-17 in patients with moderate and severe psoriasis
by: Julia S. Kovaleva, et al.
Published: (2024)

CHOICE OF THE INITIAL TREATMENT FOR MILD TO MODERATE ARTERIAL HYPERTENSION IN MOSCOW PRIMARY PRACTICE
by: S. V. Gatsura, et al.
Published: (2015)

CHOICE OF THE INITIAL TREATMENT FOR MILD TO MODERATE ARTERIAL HYPERTENSION IN MOSCOW PRIMARY PRACTICE
by: S. V. Gatsura, et al.
Published: (2015)

Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance Data
by: Emilie Sbidian, et al.
Published: (2021)

Bed Sharing in Toddlerhood: Choice Versus Necessity and Provider Guidelines
by: Lauren B. Covington PhD, RN, et al.
Published: (2019)

Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis
by: Richard B. Warren, et al.
Published: (2024)

Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials
by: Hannah Penton, et al.
Published: (2023)

Peripheral calcifying epithelial odontogenic tumor - Case report
by: Deepthi Shetty, et al.
Published: (2014)

Biologics and oral systemic treatment preferences in patients and physicians for moderate-to-severe atopic dermatitis: a discrete choice experiment in the United Kingdom and Germany
by: Nicholas Durno, et al.
Published: (2024)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022)